• Publications
  • Influence
Plasminogen activator inhibitors.
Chemicals/CAS: fibrin, 9001-31-4; plasminogen activator inhibitor, 105844-41-5; plasminogen activator, 9039-53-6; Carrier Proteins; Glycoproteins; Plasminogen Activators, EC 3.4.21.-; PlasminogenExpand
  • 353
  • 11
The Adult Netherlands Twin Register: twenty-five years of survey and biological data collection.
Over the past 25 years, the Adult Netherlands Twin Register (ANTR) has collected a wealth of information on physical and mental health, lifestyle, and personality in adolescents and adults. ThisExpand
  • 197
  • 10
  • PDF
Consumption of black and green tea has no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals
Obejective: Firstly, to study the effect of tea and tea polyphenols on cardiovascular risk indicators of the inflammatory system (IL6, IL1β and TNF-α, CRP), and on haemostasis and endothelialExpand
  • 93
  • 10
CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone.
A disturbed hypothalamus-pituitary-adrenal gland axis and alterations at the immune system level have been observed in patients with chronic fatigue syndrome (CFS). Glucocorticoids are known toExpand
  • 80
  • 10
Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
Summary Oestrogen replacement therapy is associated with a decreased risk of cardiovascular disease in postmenopausal women. Patients with non-insulin-dependent diabetes mellitus (NIDDM) have anExpand
  • 208
  • 8
  • PDF
Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke.
Natural inhibitors of endogenous fibrinolysis may displace the hemostatic equilibrium toward thrombosis and favor events such as acute myocardial infarction, sudden cardiac death and stroke, where aExpand
  • 428
  • 6
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.
Currently raloxifene, a selective estrogen receptor modulator, is being investigated as a potential alternative for postmenopausal hormone replacement to prevent osteoporosis and cardiovascularExpand
  • 163
  • 5
  • PDF
Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Circadian fluctuation in blood fibrinolytic activity was studied in 10 volunteers in the day-time period at 09.00, 12.00 and 15.00 h. Activity of tissue-type plasminogen activator (t-PA) was found toExpand
  • 188
  • 5
Effect of oral contraceptives on haemostasis variables.
Combined oral contraceptives (COCs) have effects on a large number of haemostasis variables. We have summarised literature data on effects of COCs containing 30-35 micrograms ethinyl estradiol forExpand
  • 175
  • 5
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen)
Several investigators have reported that tumor necrosis factor (TNF) can alter the production of plasminogen activator type-1 (PAI-1) and plasminogen activators (PAs) by endothelial cells in vitro.Expand
  • 113
  • 5
  • PDF